Adial Pharmaceuticals Appoints Chief Scientist to Lead AT177 Program
Adial Pharmaceuticals appointed David Rubenstein, M.D., Ph.D., as chief scientist to lead AT177 through IND-enabling work toward first-in-human trials expected in 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
Adial Pharmaceuticals Appoints David Rubenstein as Chief Scientist
Rubenstein will lead development of AT177 through IND-enabling studies toward first-in-human trials.
Adial Pharmaceuticals Appoints David Rubenstein as Chief Scientist
Adial Pharmaceuticals appointed David Rubenstein as chief scientist to lead its research and scientific strategy. Rubenstein previously served as Dermavant Sciences’ chief scientific officer, leading tapinarof development through commercialization. He will oversee AT177 development for ulcerative colitis, with first-in
Adial Pharmaceuticals appoints David Rubenstein chief scientist
David Rubenstein, M.D., Ph.D., was appointed chief scientist to advance AT177, a colon-targeted AhR agonist for ulcerative colitis.